Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea

Blood. 2015 Jun 4;125(23):3668-9. doi: 10.1182/blood-2015-03-635391.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anemia, Sickle Cell / blood*
  • Anemia, Sickle Cell / drug therapy*
  • Antisickling Agents / administration & dosage
  • Antisickling Agents / adverse effects
  • Female
  • Histone Deacetylase Inhibitors / administration & dosage*
  • Humans
  • Hydroxamic Acids / administration & dosage*
  • Hydroxyurea / administration & dosage
  • Hydroxyurea / adverse effects
  • Male
  • Vorinostat

Substances

  • Antisickling Agents
  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • Vorinostat
  • Hydroxyurea